SLNO
Soleno Therapeutics, Inc. NASDAQ Listed Nov 13, 2014$52.95
Mkt Cap $2.8B
52w Low $29.43
38.6% of range
52w High $90.32
50d MA $43.54
200d MA $53.72
P/E (TTM)
128.9x
EV/EBITDA
84.4x
P/B
6.2x
Debt/Equity
0.0x
ROE
4.6%
P/FCF
52.7x
RSI (14)
—
ATR (14)
—
Beta
-2.81
50d MA
$43.54
200d MA
$53.72
Avg Volume
3.4M
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
203 Redwood Shores Parkway · Redwood City, CA 94065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | 0.64 | 0.80 | +25.0% | 41.01 | -11.9% | -7.1% | +2.6% | -0.0% | -3.4% | +1.1% | — |
| Nov 4, 2025 | AMC | 0.06 | 0.47 | +717.4% | 63.85 | -21.9% | -26.6% | -7.1% | +9.6% | -2.9% | +5.2% | — |
| Aug 6, 2025 | AMC | -0.53 | -0.09 | +83.0% | 81.19 | +2.7% | -3.1% | +4.6% | +4.1% | -2.8% | -2.7% | — |
| May 7, 2025 | AMC | -1.14 | -0.95 | +16.7% | 74.66 | +1.3% | +2.1% | +0.7% | -0.1% | -2.9% | -1.3% | — |
| Feb 27, 2025 | AMC | -0.63 | -1.27 | -101.6% | 44.99 | -0.6% | +8.5% | -6.2% | -3.0% | +1.2% | -0.1% | — |
| Nov 6, 2024 | AMC | -0.61 | -1.83 | -200.0% | 56.86 | -2.2% | +0.4% | -0.1% | +3.7% | -3.2% | -2.8% | — |
| Aug 7, 2024 | AMC | -0.63 | -0.57 | +9.5% | 43.96 | -2.4% | +2.5% | +1.8% | +2.0% | +5.7% | -1.3% | — |
| May 9, 2024 | AMC | -0.30 | -0.59 | -96.7% | 47.64 | +0.0% | -5.6% | -4.9% | +1.6% | +3.9% | +1.0% | — |
| Mar 6, 2024 | AMC | -0.31 | -0.33 | -6.5% | 46.38 | -7.3% | -3.1% | -0.2% | -1.7% | -0.6% | +0.3% | — |
| Nov 7, 2023 | AMC | -0.62 | -0.95 | -53.2% | 23.00 | +2.1% | -4.7% | +1.0% | -0.6% | +0.4% | +2.3% | — |
| Aug 8, 2023 | AMC | -0.70 | -0.81 | -15.7% | 25.65 | +0.0% | -1.4% | -2.2% | -4.0% | -3.2% | -1.7% | — |
| May 9, 2023 | AMC | -0.71 | -0.88 | -23.9% | 21.60 | -0.5% | -6.2% | +3.7% | -1.2% | +1.4% | -6.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $52.57 | $52.62 | +0.1% | +0.4% | -0.2% | +0.0% | +0.1% | +0.2% |
| Apr 8 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $52.35 | $52.33 | -0.0% | +0.5% | -0.2% | +0.2% | +0.0% | -0.0% |
| Apr 7 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $52.25 | $52.29 | +0.1% | +0.2% | +0.5% | -0.2% | +0.2% | +0.0% |
| Apr 7 | TD Cowen | Downgrade | Buy → Hold | — | $52.25 | $52.29 | +0.1% | +0.2% | +0.5% | -0.2% | +0.2% | +0.0% |
| Apr 6 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $39.49 | $52.31 | +32.5% | +32.3% | +0.2% | +0.5% | -0.2% | +0.2% |
| Mar 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $33.62 | $33.51 | -0.3% | -2.4% | +2.5% | -1.2% | -4.5% | -1.2% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.72 | $37.80 | +0.2% | +1.1% | +1.2% | +2.9% | +0.2% | +2.1% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $38.09 | $37.85 | -0.6% | +2.6% | -0.0% | -3.4% | +1.1% | +1.2% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $41.01 | $36.14 | -11.9% | -7.1% | +2.6% | -0.0% | -3.4% | +1.1% |
| Jan 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $42.48 | $42.73 | +0.6% | +2.9% | -0.4% | +0.4% | -3.2% | +1.1% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.48 | $42.73 | +0.6% | +2.9% | -0.4% | +0.4% | -3.2% | +1.1% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $63.85 | $49.89 | -21.9% | -26.6% | -7.1% | +9.6% | -2.9% | +5.2% |
| Aug 27 | Guggenheim | Maintains | Buy → Buy | — | $69.61 | $69.30 | -0.4% | -2.8% | +1.1% | -1.1% | -0.7% | -0.4% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $71.63 | $71.35 | -0.4% | -4.9% | -1.9% | +3.2% | +1.2% | -1.8% |
| Aug 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $81.19 | $83.42 | +2.7% | -3.1% | +4.6% | +4.1% | -2.8% | -2.7% |
| Aug 7 | Guggenheim | Maintains | Buy → Buy | — | $81.19 | $83.42 | +2.7% | -3.1% | +4.6% | +4.1% | -2.8% | -2.7% |
| Jul 11 | Baird | Maintains | Outperform → Outperform | — | $80.32 | $81.77 | +1.8% | +1.6% | +1.5% | +1.0% | +2.3% | +2.5% |
| May 8 | Baird | Maintains | Outperform → Outperform | — | $74.66 | $75.66 | +1.3% | +2.1% | +0.7% | -0.1% | -2.9% | -1.3% |
| May 8 | Guggenheim | Maintains | Buy → Buy | — | $74.66 | $75.66 | +1.3% | +2.1% | +0.7% | -0.1% | -2.9% | -1.3% |
| Apr 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $72.27 | $73.24 | +1.3% | +2.7% | -1.3% | +0.5% | +2.2% | -0.5% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $70.00 | $69.79 | -0.3% | +0.4% | -0.5% | +0.1% | -1.5% | +3.6% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $71.99 | $71.54 | -0.6% | -0.8% | -4.5% | +7.9% | -2.0% | -6.5% |
| Mar 28 | Guggenheim | Maintains | Buy → Buy | — | $67.39 | $67.83 | +0.7% | +6.8% | -0.8% | -4.5% | +7.9% | -2.0% |
| Mar 28 | Stifel | Maintains | Buy → Buy | — | $67.39 | $67.83 | +0.7% | +6.8% | -0.8% | -4.5% | +7.9% | -2.0% |
| Mar 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $48.97 | $66.39 | +35.6% | +37.6% | +6.8% | -0.8% | -4.5% | +7.9% |
| Mar 27 | Laidlaw & Co. | Maintains | Buy → Buy | — | $48.97 | $66.39 | +35.6% | +37.6% | +6.8% | -0.8% | -4.5% | +7.9% |
| Mar 27 | Baird | Maintains | Outperform → Outperform | — | $48.97 | $66.39 | +35.6% | +37.6% | +6.8% | -0.8% | -4.5% | +7.9% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.82 | $48.93 | +0.2% | -6.2% | -3.0% | +1.2% | -0.1% | -0.4% |
| Dec 2 | Baird | Maintains | Outperform → Outperform | — | $52.71 | $52.75 | +0.1% | -5.1% | +2.3% | -1.0% | -2.0% | -1.0% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.71 | $52.75 | +0.1% | -5.1% | +2.3% | -1.0% | -2.0% | -1.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $57.05 | $58.40 | +2.4% | +3.7% | -3.2% | -2.8% | -2.9% | -4.2% |
| Oct 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $54.92 | $56.29 | +2.5% | +0.7% | +1.8% | -1.0% | -1.2% | +1.5% |
| Aug 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $45.91 | $47.06 | +2.5% | +2.0% | +5.7% | -1.3% | +3.2% | -4.0% |
| Jul 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $46.66 | $47.01 | +0.8% | +3.4% | +2.0% | -0.9% | -7.1% | +3.2% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $44.99 | $45.17 | +0.4% | -4.9% | +1.6% | +3.9% | +1.0% | +1.1% |
| Jan 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $40.25 | $40.29 | +0.1% | -5.7% | -5.0% | +1.8% | +1.2% | +9.2% |
| Sep 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.15 | $21.00 | -5.2% | +21.0% | -22.9% | +33.5% | +7.0% | -10.3% |
| Sep 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $21.20 | $23.20 | +9.4% | +15.6% | -3.3% | -4.9% | -8.9% | +0.0% |
| Aug 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $25.55 | $25.00 | -2.2% | -4.3% | +1.8% | -15.7% | -7.9% | -3.4% |
| May 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $27.50 | $27.55 | +0.2% | -8.5% | +4.4% | +2.3% | -1.9% | +11.6% |
| Mar 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.85 | $10.65 | -1.8% | +8.3% | +0.9% | -3.0% | -0.4% | -3.5% |
| Sep 29 | Guggenheim | Maintains | Buy → Buy | — | $139.50 | $145.50 | +4.3% | +11.3% | +21.3% | -11.3% | -7.4% | -0.5% |
| Jan 10 | Craig-Hallum | Maintains | Buy → Buy | — | $213.75 | $233.25 | +9.1% | +7.0% | +2.0% | -1.9% | -4.9% | +1.7% |
| Dec 23 | Laidlaw & Co. | Maintains | Buy → Buy | — | $129.75 | $178.50 | +37.6% | +25.4% | +28.6% | +5.7% | -9.2% | +7.1% |
| Dec 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $129.75 | $178.50 | +37.6% | +25.4% | +28.6% | +5.7% | -9.2% | +7.1% |
| Jun 22 | Roth Capital | Maintains | Buy → Buy | — | $173.70 | $258.00 | +48.5% | +33.9% | -10.6% | -10.8% | -0.8% | -4.1% |
No insider trades available.
SC TO-T/A
! Medium
Soleno Therapeutics, Inc. -- Tender Offer Amendment
Neurochem Inc. (NBIX) is acquiring Soleno Therapeutics (SLNO) for $53 per share, representing a significant premium to recent trading prices.
Apr 29
SC TO-T
! Medium
Soleno Therapeutics, Inc. -- Tender Offer Amendment
Neurochem Inc. is acquiring Soleno Therapeutics for $53 per share through a tender offer, representing a significant premium for Soleno shareholders.
Apr 28
SC TO-T
!!! Very High
Soleno Therapeutics, Inc. -- Tender Offer
Neurochem Inc. is acquiring Soleno Therapeutics for $53 per share in cash, representing a significant premium for Soleno shareholders.
Apr 20
8-K
Unknown — 8-K Filing
SLNO faces regulatory uncertainty as re-engagement with the European Medicines Agency remains unguaranteed, potentially delaying or blocking European market access for its pipeline drugs and limiting revenue growth.
Apr 7
8-K
Unknown — 8-K Filing
Neurochem/Silence Therapeutics merger is proceeding with no financing risk and a guaranteed 20-day offer period, reducing deal uncertainty and supporting stock prices through closing.
Apr 6
8-K
Unknown — 8-K Filing
Neurocrine (NBIX) is being acquired by an unidentified purchaser in a financing-certain deal, with a tender offer launching within ten business days—providing clarity on deal certainty for shareholders.
Apr 6
8-K
Unknown — 8-K Filing
Soleno Therapeutics updated its corporate bylaws, likely reflecting governance changes that could affect shareholder rights, board structure, or operational procedures—investors should monitor for detailed amendments in the full filing.
Mar 16
8-K · 8.01
!! High
Soleno Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Soleno Therapeutics appointed Mrs. Fulk as Chief Financial Officer, replacing retiring Mr. [name], signaling potential leadership changes that could affect operational strategy and investor confidence.
Feb 26
8-K
Soleno Therapeutics, Inc. -- 8-K Filing
Soleno Therapeutics reported 2025 financial results and provided updates on its U.S. VYKAT XR launch, a key commercial milestone for the rare disease-focused biopharmaceutical company.
Feb 25
Data updated apr 27, 2026 1:44am
· Source: massive.com